

Cambridge University Press

0521832489 - Molecular Pathogenesis of Virus Infections

Edited by P. Digard, A. A. Nash and R. E. Randall

Index

[More information](#)

INDEX

References to tables/figures are shown in italics

- A179L protein** 301
A224L protein 299
A238L protein 301, 302–303, 304, 308
 acquired immune response
 antigenic variation 101
 immunoprivileged site 99–100
 inadequate immune responses 100–101
 induction of tolerance 101–103
 adaptive immune response to HIV-1
 CD4⁺ T cell response 38–41
 CD8⁺ T cell response 41–43
 features associated with virus replication control 50–54
 mechanisms by which HIV-1 may evade control by 44–50
 humoral immunity 34–38
 African swine fever virus
 A179L protein 301
 A224L protein 299
 A238L 301, 302–303, 304, 308
 apoptosis 294, 298–301
 CD2v 305–306, 307
 encoded proteins
 enzymes and structural proteins 297
 involved in cell adhesion 305–306
 multigene families 297–298
 proteins modulating apoptosis 298–301
 proteins modulating signalling pathways 302–305
 EP153R 301, 306
 epidemiology 292
 genes affecting virulence 306–307
 haemorrhagic fever 291, 292, 293
 host transcriptional responses to 307–308
 p54 296, 299, 300
 pathogenesis 292–295
 replication cycle
 assembly 296
 replication and transcription 295–296
 virus entry 295
 structure 291
 aminopeptidase N 127
 antibody-dependent enhancement (ADE) 16–17, 20–21, 118, 128, 130
 antigen discovery 18
 antigenic variation 101
 antigen-presenting cells (APCs) 4, 6, 39, 40, 228
 antiretroviral therapy 23, 29
 anti-TNF therapy 284–285
 apoptosis 294, 298–301
 and human papillomaviruses 241
 death receptor pathway 242
 disruption by HPV proteins 244–247
 final common pathway 242–243
 mitochondrial pathway 242
 avoidance of 93–95
 defence mechanism 92–93
 inhibition of 95–96
 predisposition to 96–97
 apoptosome 92
 Argonaute 181, 187, 190, 193, 180
Bad 96, 242, 243, 301, 303
Bax 95
 B cells 294, 323–324, 326, 329–331
 Bcl-2 94, 95, 242, 243, 303, 325
 Bid 94, 95, 242
 BiP 94
 bovine spongiform encephalopathy (BSE) 137, 138–140, 142, 143, 145, 146, 148
 bovine viral diarrhoea virus (BVDV) 94, 96, 101–102
 Bunyamwera virus (BUNV) 259
 bystander apoptosis 115
Calcineurin 302, 303
 canine enteric coronavirus (CCoV) 125, 129
 caspases 92, 94, 95, 242, 243, 246, 273, 299, 97, 300
 CCR5 29, 30, 31, 32, 36, 41, 44, 186, 42
 CD2v 305–306, 307
 CD30 282
 CD4⁺ T cell response, HIV-1-specific 38–41
 CD4⁺ T cells 25–26, 330
 CD56 30, 31
 CD8⁺ T cells 3, 204–205, 206–209, 323, 331
 classes 8
 cytokine secretion 7–8, 9
 cytotoxicity 7
 CD8⁺ T cell response 101, 103
 contraction phase 6, 5
 expansion phase 6, 5
 HIV-1-specific 41–43
 features associated with virus replication control 50–54
 mechanisms by which HIV-1 may evade control by 44–50

Cambridge University Press

0521832489 - Molecular Pathogenesis of Virus Infections

Edited by P. Digard, A. A. Nash and R. E. Randall

Index

[More information](#)

342 Index

- maturation of responses 8–10
- memory phase 6–7, 5
- cell cycle 237–241
 - G₁/S phase 239–240
 - G₂/M phase 240–241
- central nervous system 96–97, 99–100, 101
- cervical cancer 236, 239, 247
- α chain of nascent polypeptide associated complex (α -NAC) 304
- chronic wasting disease 137, 141
- coagulation abnormalities 115–116
- cognate antigen 2, 6, 9
- complement 33–34
- corneal disease 204
- coronaviruses 125–133
 - canine enteric coronavirus (CCoV) 125, 129
 - envelope protein 130, 131
 - feline coronavirus (FCoV) 125, 126, 127–128, 129, 131
 - feline enteric coronavirus (FECV) 125, 127, 128
 - feline infectious peritonitis virus (FIPV) 125, 127, 128, 129, 130
 - genome organization and expression 130–131
 - membrane protein 127, 130, 131
 - nucleocapsid protein 127, 130, 133, 131
 - reverse genetics 131–133
 - spike protein 127, 130, 131
- cowpox virus (CPV) 277, 278, 279, 280, 281, 282, 283, 276
- CREB-binding protein (CBP) 209, 256, 261, 259
- Creutzfeldt–Jakob disease (CJD) 137, 148
- CrmB 277–278, 283–284, 275
- CrmC 278–279, 283–284, 275
- CrmD 279–280, 283–284, 275
- CrmE 280–281, 283–284, 275
- CXCR4 29, 31, 36, 44, 186, 45
- cyclin-dependent kinase inhibitors (CDKIs) 237–238, 239
- cyclin-dependent kinases (CDKs) 208, 237–238, 239, 240
- cyclins 237–238, 239, 240
- cytotoxic T lymphocytes 26, 43, 44, 46, 47, 48, 49, 51, 52, 92, 95
- DC-SIGN** 25, 39, 113, 114
- decoy TNFRs, poxvirus secreted 274–283
- deerpox virus (DPV) 275, 281, 282, 276
- dendritic cells (DCs) 25, 28–29, 34, 113–114, 115, 216, 219, 228–229
- dengue haemorrhagic fever 15–21
- dengue virus 15, 190
 - DEN-1 16, 20
 - DEN-2 16, 20
 - T-cell responses to 18–21
- diagnosing transmissible spongiform encephalopathies 141–144
- Dicer 181, 182, 187–188, 189, 192, 193, 180, 188
- DISC 242, 247, 304
- disseminated intravascular coagulation (DIC) 112, 115, 119, 292, 293
- DNA microarrays 332
- double-stranded RNA (dsRNA) 93, 95, 97, 98, 179, 181, 182, 183, 185, 187, 188, 189, 192, 217, 219, 224–225, 261, 102, 180, 255
- Drosha 181, 180
- E1 protein** 235, 236
- E1[^]E4 protein** 235, 246
- E2 protein** 235, 236, 246–247
- E4 protein** 235
- E5 protein** 235, 247
- E6 protein** 235, 237, 240, 241, 244, 246
- E7 protein** 235, 237, 239–240, 241, 246
- EBNA-1** 327, 330
- ebolaviruses
 - Ivory Coast ebolavirus 110, 111
 - Reston ebolavirus 109–110, 117
 - Sudan ebolavirus (SEBOV)
 - clinical disease 110–112
 - coagulation abnormalities 115–116
 - early events in infection 113–115
 - emergence and re-emergence 109–110
 - glycoprotein 116–118
 - intermediate events in infection 115–116
 - late events in infection 116–118
 - terminal events in infection 119
 - VP35 114–115
 - Zaire ebolavirus (ZEBOV)
 - clinical disease 110–112
 - coagulation abnormalities 115–116
 - disease models 112–113
 - early events in infection 113–115
 - emergence and re-emergence 109–110
 - glycoprotein 116–118
 - intermediate events in infection 115–116
 - late events in infection 116–118
 - terminal events in infection 119
 - VP35 114–115
- ectromelia virus (EV) 277, 279, 280, 282, 283, 284, 276
- endoplasmic reticulum 94
- envelope protein 130, 131
- EP153R protein 301, 306
- epitope/MHC complex 4, 8–9

- Epstein–Barr virus (EBV) 193, 319, 320, 323, 324, 325, 327, 328, 329
- erythroid-associated factor 144
- exposed seronegatives 24, 30, 31, 43, 55
- FADD** 242, 244, 246, 273, 304
- Fas 44, 94, 96, 247, 273, 45, 271
- feline coronavirus (FCoV) 125, 126, 127–128, 129, 131
- feline enteric coronavirus (FECV) 125, 127, 128
- feline infectious peritonitis (FIP)
- clinical features 126
 - control 129–130
 - diagnosis 128
 - pathogenesis 127–128
 - susceptibility 127
 - transmission 126
 - vaccine 129–130
- feline infectious peritonitis virus (FIPV) 125, 127, 128, 129, 130
- FLIPs/vFLIPs 95, 242, 273, 325
- flock house virus (FHV) 190, 191
- foot-and-mouth disease virus (FMDV) 99
- Gag** 34, 39, 41, 48, 49, 50
- gammaherpesviruses 319–333
- ganglia 91, 203, 204, 205, 206, 207, 209
- Gerstmann–Sträussler–Scheinker syndrome (GSS) 149, 150
- glucocorticoids 209
- glycoproteins 206, 207
- glycosylation patterns of PrP 143, 145, 139
- trans*-Golgi network 94
- gp120 28, 33, 35, 36, 37, 39, 40, 58
- gp160 36, 37
- gp41 33, 34, 36–37
- Haemagglutinin (HA)** 159, 163, 167–169
- haemorrhagic fever 109, 111–112, 119, 291, 292, 293, 110
- hepatitis B virus (HBV) 1, 7
- hepatitis C virus (HCV)
- disruption of innate immunity 228–229
 - genome 219–220
 - NS3/4A protease 216, 220, 228
 - blockade of IRF-3 activation 223–225, 228
 - disruption of RIG-I signalling 226–227
 - disruption of TLR3 signalling 225–226
 - evolution 227
 - subgenomic replicons 221–222
- herd immunity 3
- herpes simplex virus 1 (HSV-1)
- corneal disease 204
 - early genes 203, 205
 - glycoproteins 206, 207
 - ICP0 207–208
 - ICP47 208–209
 - immediate early genes 203, 205
 - late genes 203, 205
 - latency
 - CD8⁺ cells 204–205, 206–209
 - establishment of 203
 - latency-associated transcripts (LATs) 205
 - maintenance of 203–204
 - reactivation 204, 205, 206–207, 208, 209
 - recurrent disease 208–209
- HLA 31, 39, 40, 41, 43, 45, 47, 49, 52, 53–54, 42
- host susceptibility to transmissible spongiform encephalopathies 147–150
- human immunodeficiency virus (HIV) 185, 186, 254, 258
- human immunodeficiency virus type 1 (HIV-1)
- adaptive immune response to
 - CD4⁺ T cell response 38–41
 - CD8⁺ T cell response 41–43
 - features associated with virus replication control 50–54
 - mechanisms by which HIV-1 may evade control by 44–50
 - humoral immunity 34–38
 - antiretroviral therapy 23, 29
 - course of infection 25–26
 - Gag 34, 39, 41, 48, 49, 50
 - gp120 28, 33, 35, 36, 37, 39, 40, 58
 - gp160 36, 37
 - gp41 33, 34, 36–37
 - innate immune response to
 - complement 33–34
 - natural killer cells 29–31
 - natural T lymphocytes and $\gamma\delta$ T cells 31–32
 - type I interferons 28–29
 - Nef protein 31, 39–40, 44, 45–46, 51
 - Tat protein 39, 46, 51
 - vaccine development 23, 24, 38, 54–61
 - Vpu protein 39, 46
- human papillomaviruses (HPVs)
- apoptosis 241
 - death receptor pathway 242
 - disruption by HPV proteins 244–247
 - final common pathway 242–243
 - mitochondrial pathway 242

Cambridge University Press

0521832489 - Molecular Pathogenesis of Virus Infections

Edited by P. Digard, A. A. Nash and R. E. Randall

Index

[More information](#)**344** Index

- cell cycle disruption 237, 238–239
 G₁/S phase 239–240
 G₂/M phase 240–241
 E1 protein 235, 236
 E1[^]E4 protein 235, 246
 E2 protein 235, 236, 246–247
 E4 protein 235
 E5 protein 235, 247
 E6 protein 235, 237, 240, 241, 244, 246
 E7 protein 235, 237, 239–240, 241, 246
 infection and neoplasia 235–237, 241, 248
- ICP0 207–208
 ICP47 208–209
 I κ B 302–303
 immunoprivileged site 99–100
 influenza A virus 258, 261
 influenza pandemics and epidemics in humans 160–161
 influenza viruses
 H5N1/97 in Asia 162–163, 169
 H5N1/04 in Asia 171, 172, 173, 174, 163, 169
 H5N1 endemic in Asia? 165
 H5N1 with novel properties 163–164
 NS1 protein 191–192
 pathogenicity
 HA role 167–169
 NS gene/NS1 protein role 170–171
 PB2 role 169–170
 recombination 167–168
 reverse genetics 165–166, 172
 Spanish, 1918 160–161, 168–169, 170, 171, 174
 vaccine strain 172, 174
 with pathogenic potential 160, 161
 Z genotype of H5N1 164, 165, 163
 inhibitor of apoptosis proteins (IAPs) 243, 299, 301
 innate immune response
 avoidance of IFN triggering 98
 suppression of IFN responses 98–99
 innate immune response to HIV-1
 complement 33–34
 natural killer cells 29–31
 natural T lymphocytes and $\gamma\delta$ T cells 31–32
 type I interferons 28–29
 innate immunity 2
 interferon (IFN) 7, 9, 17, 28–29, 93–94, 97–99, 102, 114–115, 207–208, 209, 216, 217–219, 225, 228, 229, 254–262, 281, 330, 331–333
 interferon regulatory factor 3 (IRF-3) 97, 98, 99, 217–219, 223–225, 226, 256, 261, 255, 259
 interferon regulatory factor 7 (IRF-7) 218, 219, 226, 256, 255
 interferon-stimulated genes (ISGs) 216, 217, 218, 219, 254, 256, 257, 255
 interleukins 17, 30, 50, 112, 116, 209, 281, 294, 308, 332
 iridoviruses 282–283
 Ivory Coast ebolavirus 110, 111
- Jak/STAT pathway** 218, 256, 261, 332–333, 255
- Kaposi's sarcoma-associated herpesvirus (KSHV)** 319, 320, 325, 327, 328, 332, 329
- LANA-1** 327–328
 latency
 herpes simplex virus 1 (HSV-1)
 CD8⁺ cells 204–205, 206–209
 establishment of 203
 latency-associated transcripts (LATs) 205
 maintenance of 203–204
 murid herpesvirus 4 (MuHV-4) 323–324, 326–328, 329
 latency-associated transcripts (LATs) 205
 LMP1 274
 long-term non-progressors (LTNPs) 24, 29, 39, 40, 43, 51, 54, 57, 27
 lymphocytic choriomeningitis virus (LCMV) 7, 9, 102–103
 lymphotoxin (LT α) 270, 272, 277, 278, 279, 280, 271
- M2 gene** 326
 malignant catarrhal fever 319
 Marburg virus (MARV)
 clinical disease 111–112
 coagulation abnormalities 115–116
 early events in infection 113–115
 emergence and re-emergence 109–110
 glycoprotein 116–118
 intermediate events in infection 115–116
 late events in infection 116–118
 terminal events in infection 119
 VP35 114–115
 matrix protein long 260–261, 259
 measles virus (MV) 91, 99, 100–101
 membrane protein 127, 130, 131
 MHC class I 18, 19, 30, 31, 32, 45, 46, 51, 99, 100, 119, 204, 205–206, 208, 331
 anatomical distribution 4
 interactions with CD4 and CD8 4
 source of epitopes 4

- MHC class II 18, 128
 anatomical distribution 4
 interactions with CD4 and CD8 4
 source of epitopes 4
- micro-RNAs (miRNAs) 181, 192, 193
- mononucleosis 319, 323
- M-T2 276–277, 284
- murid herpesvirus 4 (MuHV-4)
 antiviral immune responses to 329–331
 B cells 323–324, 326, 329–331
 CD4⁺ T cells 330
 CD8⁺ T cells 323, 331
 control by type I interferons 331–333
 DNA microarrays 332
 experimental infection with 322–325
 genome 325
 latency 323–324, 326–328, 329
 M2 gene 326
 natural history 321–322
 ORF73 326–328, 332, 329
 reactivation 326, 327
 Rta 328, 332, 329
 vCKBP 331
- Mx1 254, 257, 260, 261
- MxA 254, 257, 260
- myxoma virus (MV) 276–277, 284
- Natural killer (NK) cells** 2, 29–31
- Nef protein 31, 39–40, 44, 45–46, 51, 96
- neoplasia 235–237, 241, 248
- neuraminidase (NA) 159, 163
- neuronal loss 137, 138, 142
- neurons 96–97, 100, 101, 203, 204–206, 207, 208, 209
- neutralization escape mutants 35, 37
- neutralizing antibodies (nAbs) 34–35, 37–38, 43, 55–56, 57
- NFAT 302, 303–304
- nitric oxide 118
- Nodamura virus (NoV) 190, 192
- NS1 protein 159, 170–171, 191–192, 163
- NS3/4A protease 216, 220, 228
 blockade of IRF-3 activation 223–225
 disruption of RIG-I signalling 226–227
 disruption of TLR3 signalling 225–226
 evolution 227
- NSs 258–259
- nuclear factor (NF)- κ B 97, 99, 216, 217, 219, 229, 299, 301, 302–303
- nucleocapsid protein 95, 127, 130, 133, 131
- 2'-5'-Oligoadenylate synthetases 94, 98, 254, 256, 257, 102, 255
- ORF73 326–328, 332, 329
- original antigenic sin 20, 21, 60
- P53** 239, 240, 244, 299, 328, 300
- p54 296, 299, 300
- pathogen-associated molecular patterns (PAMPs) 217
- perforin 7
- pol I/II/III 165–166, 182
- poliovirus (PV) 94, 96, 184–185
- polymerase PB2 159, 165, 169–170, 163
- poxviruses 274–285
- primary immune response 3, 9
- prion hypothesis 145, 147, 150–152
- prions, yeast 151
- promyelocytic leukaemia protein (PML) 257, 258
- proteasome 207, 208
- protein kinase R (PKR) 93, 94, 97, 98, 183, 192, 256, 257, 102
- PrP 138, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149–150, 151, 139
- PrP^C 138, 145, 151
- PrP-res 138, 140, 142–143, 144, 149, 150, 151, 152
- PrP^{Sc} 138, 142, 144, 145, 146, 152
- RANTES** 32, 41, 206, 223, 229
- rapid progressors 24, 29, 27
- reactivation 204, 205, 206–207, 208, 209, 326, 327
- Reaper 99
- Reston ebolavirus 109–110, 117
- reverse genetics 131–133, 165–166, 172, 187
- Rift Valley fever virus (RVFV) 258–259
- RIG-I 219, 226–227, 228, 218
- RISC 181, 183–185, 192, 180
- RNAi (RNA interference)
 as an experimental tool 182–183
 as an innate antiviral mechanism 187–193
 as a therapeutic antiviral approach 183–187
- Epstein–Barr virus 193
- flock house virus 190, 191
- human immunodeficiency virus 185, 186
- in mammals 191–193
- mechanism 180–182
- Nodamura virus 190, 192
- pathway 180
- poliovirus 184–185
- Sindbis virus 190
- transposon silencing 188
- versus viruses in insects 190–191
- versus viruses in plants 189–190
- virus escape from 185

346 Index

RNase-L 94, 98, 102

Rta 328, 332, 329

SCID mice 2

scrapie 137, 138, 140, 143, 144, 146–147, 151

secondary immune response 3

Semliki Forest virus (SFV) 96–97

Sendai virus 222–224, 226, 227

Shope fibroma virus (SFV) 275–276

short hairpin RNA (shRNA) 182, 183, 192

simian immunodeficiency virus (SIV) 32, 35, 37,
38, 47, 51, 52, 55, 320

Sindbis virus (SINV) 190

small interfering RNAs (siRNAs) 181, 182, 183,
185, 186–187, 188, 189, 190, 191, 192, 180

spike protein 127, 130, 131

sporadic Creutzfeldt–Jakob disease (sCJD) 140,
145, 147, 150, 148

S-T2 275–276, 277

STAT pathway 98

STAT proteins 99, 256

subacute sclerosing panencephalitis 92, 100, 101

Sudan ebolavirus (SEBOV)

clinical disease 110–112

coagulation abnormalities 115–116

early events in infection 113–115

emergence and re-emergence 109–110

glycoprotein 116–118

intermediate events in infection 115–116

late events in infection 116–118

terminal events in infection 119

VP35 114–115

swinepox virus (SPV) 275, 281, 276

Tanapox virus (TPV) 281–282, 276

Tat protein 39, 46, 51

T-cell responses to dengue virus 18–21

Theiler's murine encephalomyelitis virus (TMEV)
100

Thogoto virus (THOV) 259–260, 261

tick-borne encephalitis virus 17

tissue factor (TF) 115–116

T lymphocytes and $\gamma\delta$ T cells 31–32

TNFRI 270, 272, 273, 279, 280, 282

TNFRII 270, 272, 273, 275, 276, 277, 278, 279,
280, 282Toll-like receptors 93, 94, 97, 98, 217, 219,
225–226, 227, 256, 102, 218

TRAFs (TNFR-associated factors) 272, 274

TRAIL 94, 96, 115, 242, 247, 271

transmissible spongiform encephalopathies
blood transmission 141, 144

bovine spongiform encephalopathy (BSE)

137, 138–140, 142, 143, 145, 146, 148

chronic wasting disease 137, 141

Creutzfeldt–Jakob disease (CJD) 137, 148

defining strains 144–145

diagnosing 141–144

host susceptibility 147–150

nature of the agent 150–152

neuronal loss 137, 138, 142

new strains 145–147

PrP 138, 140, 141, 142, 143, 144, 145, 146, 147,
148, 149–150, 151, 139PrP^C 138, 145, 151PrP-res 138, 140, 142–143, 144, 149, 150, 151,
152PrP^{Sc} 138, 142, 144, 145, 146, 152scrapie 137, 138, 140, 143, 144, 146–147,
151

sporadic Creutzfeldt–Jakob disease (sCJD)

140, 145, 147, 150, 148

vacuolation 137, 138, 142, 144

variant Creutzfeldt–Jakob disease (vCJD)

138, 140–141, 142, 144, 145, 147, 148

transposon silencing 188

TRIF 217, 218, 226, 227

TRIM proteins 254, 257, 258

tumour necrosis factor (TNF) 7, 9, 94, 242, 244,
246

structure and biological activity 269–270

TNFRI 270, 272, 273, 279, 280, 282

TNFRII 270, 272, 273, 275, 276, 277, 278, 279,
280, 282TNFR superfamily (TNFRSF) 270–273,
274

TNF superfamily (TNFSF) 270, 271

modulation of activity by viruses

273–274

vTNFBPs 274, 275, 281–282

vTNFRs 274–281, 282–283, 284

tumour necrosis factor alpha (TNF- α) 17, 293,
294, 304, 308**Vaccination** 2, 6–7

vaccine

for feline infectious peritonitis 129–130

for HIV-1 23, 24, 38, 54–61

vaccine strain of influenza 172, 174

vaccinia virus (VV) 129–130, 131–133, 278, 279,
280, 281, 283, 284, 276

vacuolation 137, 138, 142, 144

variant Creutzfeldt–Jakob disease (vCJD) 138,
140–141, 142, 144, 145, 147, 148

varicella-zoster virus (VZV) 91, 92

Cambridge University Press

0521832489 - Molecular Pathogenesis of Virus Infections

Edited by P. Digard, A. A. Nash and R. E. Randall

Index

[More information](#)Index **347**

variola virus (VaV) 277, 278, 283, 284, 276
vCD30 282, 275
vCKBP 331
v-cyclin 326
vFLIPs 95, 273, 325
VP35 114–115
V protein 99, 101
Vpu protein 39, 46
vTNFBPs 274, 275, 281–282
vTNFRs 274–281, 282–283, 284
Yaba-like disease virus (YLDV) 281, 276
Yaba monkey tumour virus (YMTV) 281

Zaire ebolavirus (ZEBOV)
clinical disease 110–112
coagulation abnormalities 115–116
disease models 112–113
early events in infection 113–115
emergence and re-emergence 109–110
glycoprotein 116–118
intermediate events in infection 115–116
late events in infection 116–118
terminal events in infection 119
VP35 114–115
Z genotype of H5N1 164, 165, 163